潰瘍性大腸炎(UC)の成人におけるベドリズマブとトファシチニブの研究
中等度から重度の活動性潰瘍性大腸炎の成人患者を対象としたトファシチニブによるベドリズマブ二重標的療法の反応と寛解の誘導を評価する非盲検、第 4 相、単群、多施設共同研究
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with vedolizumab alone after the double treatment.
All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks.
Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.
調査の概要
詳細な説明
The drugs being tested in this study are called Vedolizumab and Tofacitinib. Vedolizumab and Tofacitinib dual targeted therapy is being tested to treat people with moderate to severe UC who have experienced inadequate response, loss of response or intolerance to no more than 2 prior tumor necrosis factor (TNF) antagonists. This study will look at the clinical remission in people who take Vedolizumab and Tofacitinib dual targeted therapy.
The study will enroll approximately 60 participants. All the participants will be enrolled in a single treatment group to receive dual targeted treatment with Vedolizumab and Tofacitinib for the first 8 weeks:
Vedolizumab 300 mg + Tofacitinib 10 mg
Only those participants who show a clinical response at Week 8 will transition to Vedolizumab monotherapy for 44 weeks.
This multi-center trial will be conducted in the United States and Canada. The overall duration of the study is up to 76 weeks. Participants will be followed up for 26 weeks after the last dose of the study drug for safety.
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究場所
-
-
Alabama
-
Dothan、Alabama、アメリカ、36301
- Digestive Health Specialsits
-
-
Arizona
-
Sun City、Arizona、アメリカ、85351
- GI Alliance Sun City
-
-
California
-
Los Angeles、California、アメリカ、90048
- Cedars-Sinai Medical Center
-
Newport Beach、California、アメリカ、92663
- Hoag Hospital Newport Beach
-
-
Florida
-
Orlando、Florida、アメリカ、32803
- Endoscopic Research Inc
-
Tampa、Florida、アメリカ、33615
- Alliance Clinical Research of Tampa, LLC
-
-
Georgia
-
Roswell、Georgia、アメリカ、30076
- Gastroenterology Consultants, P.C.
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- University of Chicago Medicine
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- University of Kansas Medical Center
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- University of Louisville
-
-
Louisiana
-
Metairie、Louisiana、アメリカ、70006
- GI Alliance
-
New Orleans、Louisiana、アメリカ、70112
- Tulane University
-
-
Maryland
-
Chevy Chase、Maryland、アメリカ、20815
- Capital Digestive Care - MGG Group - Chevy Chase Clinical Research
-
-
Michigan
-
Ypsilanti、Michigan、アメリカ、48197
- Huron Gastroenterology Associates, P.C.
-
-
Minnesota
-
Plymouth、Minnesota、アメリカ、55446
- MNGI Digestive Health, PA
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- Mid-America Gastro-Intestinal Consultants
-
Liberty、Missouri、アメリカ、64068
- BVL Clinical Research
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
-
New York
-
New York、New York、アメリカ、10016
- NYU Langone Health
-
New York、New York、アメリカ、10065
- Weill Cornell Medical College- New York Presbyterian Hospital
-
-
North Carolina
-
Asheville、North Carolina、アメリカ、28801
- Digestive Health Partners
-
Chapel Hill、North Carolina、アメリカ、27599
- University of North Carolina
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45627
- University of Cincinnati
-
Columbus、Ohio、アメリカ、43202
- Ohio Gastroenterology group, Inc.
-
Westlake、Ohio、アメリカ、44145
- Gastro Intestinal Research Institute of Northern Ohio, LLC.
-
-
Pennsylvania
-
Wexford、Pennsylvania、アメリカ、15090
- Allegheny Health Network
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02094
- University Gastroenterology
-
-
South Dakota
-
Rapid City、South Dakota、アメリカ、57701
- Sanford Health Research
-
-
Texas
-
Houston、Texas、アメリカ、77030
- The University of Texas Health Science Center at Houston
-
Mansfield、Texas、アメリカ、76063
- GI Alliance - Mansfield
-
San Antonio、Texas、アメリカ、78229
- Gastroenterology Research of San Antonio, LLC
-
Southlake、Texas、アメリカ、76092
- Texas Digestive Disease Consultants (TDDC), Southlake
-
Tyler、Texas、アメリカ、75701
- Tyler Research Institute, LLC
-
Webster、Texas、アメリカ、77598
- GI Alliance - Webster
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84108
- University of Utah Health
-
-
Washington
-
Tacoma、Washington、アメリカ、98405
- Washington Gastroenterology- GIA
-
-
-
-
Ontario
-
Barrie、Ontario、カナダ、L4M 7G1
- Barrie GI Associates Inc.
-
London、Ontario、カナダ、N6A 5A5
- London Health Sciences Centre
-
Mississauga、Ontario、カナダ、L5M 7N4
- West GTA Endoscopy Inc.
-
North Bay、Ontario、カナダ、P1B 2H3
- Viable Clinical Research - North Bay
-
North York、Ontario、カナダ、M6A3B4
- Toronto Immune and Digestive Health Institute Inc. (TIDHI)
-
Oakville、Ontario、カナダ、L6L 5L7
- ABP Research Services Corp.
-
Oshawa、Ontario、カナダ、L1J 0C7
- Taunton Surgical Centre
-
Vaughan、Ontario、カナダ、L4L 4Y7
- Toronto Digestive Disease Associates (TDDA) Inc.
-
-
Quebec
-
Montreal、Quebec、カナダ、H3G 1A4
- The Research Institute of the McGill University Health Centre
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Has a confirmed diagnosis of UC established at least 3 months prior to screening, by clinical and endoscopic evidence and corroborated by a histopathology report.
- Has moderately to severely active UC as determined by a complete Mayo score [including PGA] of 6 to 12 with a rectal bleeding subscore ≥1 and a centrally assessed endoscopic subscore ≥2 at screening.
- Has evidence of UC extending proximally to the rectum [≥15 centimeter (cm) of involved colon].
- Participants with extensive colitis or pancolitis of >8 years duration or left sided colitis >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months of the initial screening visit.
- Participants with a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factors must be up to date on colorectal cancer surveillance.
- Has demonstrated an inadequate response to, loss of response to, or intolerance to at least 1, but no more than 2 TNFα antagonists. Determination of inadequate response, loss of response, or intolerance is based upon investigator's clinical judgment. Participants who discontinued TNFα antagonist therapy for reasons other than failure or intolerance (eg, pregnancy) may be eligible after discussion with the medical monitor.
Note: After the interim analysis, participants with inadequate response, loss of response, or intolerance to conventional UC therapy per standard of care treatment without prior exposure to biologics may be enrolled if deemed appropriate. Determination of inadequate response, loss of response, or intolerance is based upon investigator's clinical judgment. Participants who discontinued biologics for reasons other than failure or intolerance (eg, pregnancy) may be eligible after discussion with the Medical Monitor. If using corticosteroids must be on a stable dose of oral corticosteroids up to a maximum of 40 mg daily of prednisone or 9 mg daily of budesonide, or equivalent for at least 2 weeks prior to screening endoscopy and must be willing to follow a mandatory taper of corticosteroids.
Exclusion Criteria:
Gastrointestinal Exclusion criteria:
-
Has any of the following UC-related complications:
- Acute severe UC.
- The participant has had extensive colonic resection, subtotal or total colectomy.
- The participant has clinical evidence of abdominal abscess or toxic megacolon.
- The participant has an ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
- Short bowel syndrome.
-
Has Crohn's colitis, indeterminate colitis, ischemic colitis, nonsteroidal anti-inflammatory drug (NSAID) induced colitis, idiopathic colitis (i.e, colitis not consistent with UC), radiation colitis, microscopic colitis, colonic mucosal dysplasia, or untreated bile acid malabsorption. Participants with a history of colonic mucosal dysplasia are also excluded.
-
Has uncontrolled primary sclerosing cholangitis.
Infectious Disease Exclusion Criteria:
-
Has any evidence of an active systemic infection during screening. Participants with nonsystemic infections (eg, active fungal infection of nail beds) may be eligible, if in the opinion of the investigator, inclusion of the participant will not interfere with the collection or interpretation of study results and poses no risk to the participant.
-
Has active or latent tuberculosis (TB), regardless of treatment history, as evidenced by any of the following:
- History of TB.
- A diagnostic TB test performed during screening that is positive, as defined by:
i. A positive QuantiFERON test or 2 successive indeterminate QuantiFERON tests or ii. A tuberculin skin test reaction ≥10 mm (≥5 mm in participants receiving the equivalent of >15 mg daily prednisone).
-
A positive test for hepatitis B virus (HBV).
-
A positive test for hepatitis C virus (HCV).
-
Evidence of, or treatment for, Clostridium difficile infection or other intestinal pathogen during screening. Participants who test positive for C. difficile or other intestinal pathogens at screening and receive treatment may be enrolled or rescreened (if required) following confirmation of infection resolution.
-
Evidence of active Cytomegalovirus (CMV) infection at screening.
Medication exclusion criteria:
-
Has received immunomodulators (eg, 6-mercaptopurine, azathioprine, and methotrexate) within 4 weeks prior to first dose or immunosuppressants (eg, cyclosporine, tacrolimus) within 8 weeks prior to first dose.
-
Any medicinal product, herbal medication, or natural health product which might interfere with cytochrome P450 genotype 3A4 (CYP3A4) within 2 weeks prior to enrollment, except for any CYP3A4 modulator used to treat a C. difficile or an intestinal pathogen infection at screening.
-
Has received any of the following medical therapies for UC:
- IV antibiotics within 8 weeks prior to enrollment.
- Any rectal therapy for treatment of UC within 2 weeks prior to screening endoscopy.
- Chronic NSAID use defined as daily use for >2 consecutive weeks (Note: occasional use [<2 consecutive weeks] of NSAIDs and acetaminophen [<100 mg daily] for headache, arthritis, myalgias, or menstrual cramps and chronic low dose aspirin use [81-162.5 mg daily] for cardiovascular prophylaxis are permitted).
-
Has received a live vaccine within 4 weeks prior to first dose.
General Exclusion Criteria:
-
Has any of the following cardiovascular or thrombotic conditions:
- Recent (within past 6 months) cerebrovascular accident, myocardial infarction, or coronary stenting.
- Recent (within past 6 months) moderate to severe congestive heart failure (New York Heart Association class III or IV).
- Prior history of thrombotic events, including deep vein thrombosis and pulmonary embolism.
- Known inherited conditions that predispose to hypercoagulability.
-
History of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
-
A surgical procedure requiring general anesthesia within 3 months prior to screening or is planning to undergo major surgery during the study period.
-
Any investigational procedure ≤4 weeks prior to screening that, in the investigator's opinion, may interfere with interpretation of study results.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Vedolizumab 300 mg + Tofacitinib 10 mg
Participants will receive Vedolizumab 300 mg, intravenous (IV) infusion, at Week 0, Week 2 and Week 6 along with Tofacitinib 10 mg, tablets, orally, twice daily from Week 0 to Week 8. Participants with clinical response at Week 8 will transition to receive vedolizumab 300 mg IV infusion every 8 weeks (Q8W) through Week 46. |
Vedolizumab IV infusions
他の名前:
Tofacitinib Tablets
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Achieving Clinical Remission at Week 8 Based on Complete Mayo Score
時間枠:At Week 8
|
Clinical remission based on complete Mayo Score is where a participant achieves complete Mayo Score ≤2 points with no individual subscore >1 at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a Physician's Global Index (PGA) and Mayo endoscopic findings (MES). Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity. |
At Week 8
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Achieving Clinical Remission at Week 52 Based on Complete Mayo Score
時間枠:At Week 52
|
Clinical remission based on complete Mayo Score is where a participant achieves complete Mayo Score ≤2 points with no individual subscore >1 at Week 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity. |
At Week 52
|
|
Percentage of Participants Achieving Clinical Remission at Weeks 8, 14, and 26 Based on Partial Mayo Score
時間枠:At Weeks 8, 14 and 26
|
Clinical remission based on complete Mayo Score is where a participant achieves partial Mayo Score ≤2 points with no individual subscore >1. Partial Mayo Score consists of 3 variables of the Mayo Clinic Score: stool frequency, rectal bleeding and PGA. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease. These scores are summed to give a total score range of 0 to 9 where higher scores indicate maximum disease activity. |
At Weeks 8, 14 and 26
|
|
Percentage of Participants Achieving Clinical Response at Weeks 2, 6, 8, 14, 26 and 52 Based on Complete or Partial Mayo Score
時間枠:At Weeks 2, 6, 8, 14, 26, and 52
|
Clinical response based on complete Mayo Score is where a participant achieves a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline or a partial Mayo score of ≥2 points and ≥25% from baseline, if the complete Mayo score was not performed at the visit with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity. |
At Weeks 2, 6, 8, 14, 26, and 52
|
|
Percentage of Participants Achieving Clinical Remission at Week 8 and Week 52 Based on Modified Mayo Score
時間枠:At Weeks 8 and 52
|
Clinical remission based on modified Mayo Score is where a participant achieves component modified Mayo score of ≤2 with modified MES ≤1, rectal bleeding = 0, and stool frequency ≤1. Modified Mayo Score consists of 3 variables: stool frequency, rectal bleeding and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease. These scores are summed to give a total score range of 0 to 9 where higher scores indicate maximum disease activity. |
At Weeks 8 and 52
|
|
Percentage of Participants With Endoscopic Improvement at Week 8 and Week 52 Based on Modified Mayo Endoscopic Subscore (MMES)
時間枠:At Weeks 8 and 52
|
Endoscopic improvement based on modified mayo endoscopic score is where participants achieve MMES ≤1 point. The subscale is graded from 0 to 3 based on the findings on endoscopy were 0= Normal appearance of mucosa, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher scores indicate more severe disease. |
At Weeks 8 and 52
|
|
Percentage of Participants With Durable Clinical Remission at Week 8 and Week 52
時間枠:At Week 8 and Week 52
|
Durable clinical remission is defined as the clinical remission at Week 8 and Week 52. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Weeks 8 and 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity. |
At Week 8 and Week 52
|
|
Percentage of Participants Using Oral Corticosteroids at Baseline Achieving Clinical Remission at Week 8
時間枠:At Week 8
|
Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity. |
At Week 8
|
|
Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 8
時間枠:At Week 8
|
Corticosteroid-free clinical remission is where a participant achieves corticosteroid-free clinical remission at Week 8. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity. |
At Week 8
|
|
Percentage of Participants Using Oral Corticosteroids at Baseline Achieving Clinical Remission at Week 52
時間枠:At Week 52
|
Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 52. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity. |
At Week 52
|
|
Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 52
時間枠:At Week 52
|
Corticosteroid-free clinical remission is where a participant achieves corticosteroid-free clinical remission at Week 52, and was off corticosteroids at least 3 months prior to Week 52. Clinical remission is defined as complete Mayo Score of ≤2 points and no individual subscore >1 point at Week 8. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity. |
At Week 52
|
|
Percentage of Participants Achieving Clinical Response at Week 8
時間枠:At Week 8
|
Clinical response based on complete Mayo Score is where a participant achieves a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The complete Mayo Clinic Score includes 4 variables: Stool frequency, rectal bleeding, a PGA and MES. Each variable is scored on a 4-point scale (0-3 points) where 0=none and 3=severe disease and summed to give a total disease activity score (range, 0-12), with higher scores representing more severe disease activity. |
At Week 8
|
|
Percentage of Participants With Endoscopic Improvement at Week 52
時間枠:At Week 52
|
Endoscopic improvement based on modified mayo score is where participants achieve MMES ≤1 point. The subscale is graded from 0 to 3 based on the findings on endoscopy were 0= Normal appearance of mucosa, 1=mild disease (erythema, decreased vascular pattern), 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3=severe disease (spontaneous bleeding, ulceration). Higher scores indicate more severe disease. |
At Week 52
|
|
Percentage of Participants With Histological Remission Based on Geboes Score at Week 52
時間枠:At Week 52
|
Histological remission is defined as Geboes score <2 at Week 52. The Geboes score is a histological grading system for assessing histological disease activity in UC. The Geboes score evaluates 7 histological features. It consists of 6 grades (0-6). Each of the grades is divided into subgrades, based on the severity of tissue abnormalities or the extent of inflammatory cell infiltration. The Geboes score ranges from 0.0 to 5.4, and higher grades are indicative of more severe disease activity. |
At Week 52
|
|
Change in C-Reactive Protein Levels (CRP) From Baseline
時間枠:Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52
|
CRP is a useful marker of inflammation in participants with inflammatory bowel disease (IBD). In participants with UC, elevated CRP has been associated with severe clinical activity. |
Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52
|
|
Change in Fecal Calprotectin Concentrations From Baseline
時間枠:Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52
|
Fecal calprotectin is a biomarker for intestinal inflammatory activity. |
Baseline to Weeks 2, 6, 8, 14, 26, 38 and 52
|
|
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score From Baseline
時間枠:At Weeks 8, 26 and 52
|
The IBDQ is an instrument used to assess quality of life in adult participants with inflammatory bowel disease (IBD). It includes 32 questions on 4 domains of Health-Related Quality-of-Life (HRQOL): Bowel Systems (10 items), Emotional Function (12 items), Social Function (5 items), and Systemic Function (5 items). Participants are asked to recall symptoms and quality of life from the last 2 weeks and rate each item on a 7-point Likert scale (1=worst to 7=best). A total IBDQ score is calculated by summing the scores from each domain; the total IBDQ score ranges from 32 to 224, with lower scores reflecting worse HRQOL. A positive change from Baseline indicates improvement. |
At Weeks 8, 26 and 52
|
|
Change in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Score From Baseline
時間枠:At Weeks 8, 26 and 52
|
The FACIT-F is a validated, 13-item questionnaire to assess fatigue in participants with a variety of chronic illnesses, including participants with IBD. Items are rated on a 5-point Likert scale and the total score ranges from 0 to 52 with lower scores representing greater fatigue. |
At Weeks 8, 26 and 52
|
|
Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)
時間枠:Up to 76 weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence is considered related to the study intervention. |
Up to 76 weeks
|
|
Number of Participants With Clinically Significant Change in Vital Signs From Baseline
時間枠:Up to 76 weeks
|
Vital signs will include body temperature, respiratory rate, blood pressure (resting more than 5 minutes), and pulse (resting more than 5 minutes). |
Up to 76 weeks
|
|
Number of Participants With Clinically Significant Physical Examination Findings
時間枠:At Baseline and From Week 14 to Week 72
|
A baseline physical examination (defined as the assessment before first dose of study medication) will consist of the following body systems: general appearance; HEENT (head, eyes, ears, nose, and throat); cardiovascular system; respiratory system; gastrointestinal system; dermatologic system; extremities; musculoskeletal system; nervous system; lymph nodes; and other. All subsequent physical examinations will assess clinically significant changes from the assessment prior to first dose examination. |
At Baseline and From Week 14 to Week 72
|
|
Number of Participants With Markedly Abnormal Laboratory Values
時間枠:Up to 76 weeks
|
Standard laboratory tests will include clinical chemistry, hematology, coagulation and urinalysis. |
Up to 76 weeks
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Study Director、Takeda
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- Vedolizumab-4054
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD 共有アクセス基準
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。